Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ropsacitinib in moderate to severe ulcerative colitis
NCT04209556Phase 2Withdrawn
- Sponsor
- Pfizer
- Start
- Sep 2020
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ropsacitinib in ulcerative colitis (UC), sponsored by Pfizer. Planned start Sep 2020; status: withdrawn.
02
Drugs
ropsacitinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04209556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04209556.